343 related articles for article (PubMed ID: 21211565)
1. Tissue-specific function of farnesoid X receptor in liver and intestine.
Zhu Y; Li F; Guo GL
Pharmacol Res; 2011 Apr; 63(4):259-65. PubMed ID: 21211565
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine.
Thomas AM; Hart SN; Kong B; Fang J; Zhong XB; Guo GL
Hepatology; 2010 Apr; 51(4):1410-9. PubMed ID: 20091679
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine.
Kim I; Ahn SH; Inagaki T; Choi M; Ito S; Guo GL; Kliewer SA; Gonzalez FJ
J Lipid Res; 2007 Dec; 48(12):2664-72. PubMed ID: 17720959
[TBL] [Abstract][Full Text] [Related]
4. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.
Maran RR; Thomas A; Roth M; Sheng Z; Esterly N; Pinson D; Gao X; Zhang Y; Ganapathy V; Gonzalez FJ; Guo GL
J Pharmacol Exp Ther; 2009 Feb; 328(2):469-77. PubMed ID: 18981289
[TBL] [Abstract][Full Text] [Related]
6. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk.
Lien F; Berthier A; Bouchaert E; Gheeraert C; Alexandre J; Porez G; Prawitt J; Dehondt H; Ploton M; Colin S; Lucas A; Patrice A; Pattou F; Diemer H; Van Dorsselaer A; Rachez C; Kamilic J; Groen AK; Staels B; Lefebvre P
J Clin Invest; 2014 Mar; 124(3):1037-51. PubMed ID: 24531544
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of the intestinal nuclear bile acid farnesoid X receptor (FXR) by the caudal-related homeobox 2 (CDX2).
Modica S; Cariello M; Morgano A; Gross I; Vegliante MC; Murzilli S; Salvatore L; Freund JN; Sabbà C; Moschetta A
J Biol Chem; 2014 Oct; 289(41):28421-32. PubMed ID: 25138215
[TBL] [Abstract][Full Text] [Related]
8. Targeting farnesoid X receptor for liver and metabolic disorders.
Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
[TBL] [Abstract][Full Text] [Related]
9. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
10. Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency.
Huang M; Kong B; Zhang M; Rizzolo D; Armstrong LE; Schumacher JD; Chow MD; Lee YH; Joseph LB; Stofan M; Zhang L; Guo GL
Lab Invest; 2020 Sep; 100(9):1158-1168. PubMed ID: 32404932
[TBL] [Abstract][Full Text] [Related]
11. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
12. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
14. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
Deng W; Fan W; Tang T; Wan H; Zhao S; Tan Y; Oware KA; Tan J; Li J; Qu S
Oxid Med Cell Longev; 2022; 2022():3589525. PubMed ID: 35251469
[TBL] [Abstract][Full Text] [Related]
16. FXR an emerging therapeutic target for the treatment of atherosclerosis.
Mencarelli A; Fiorucci S
J Cell Mol Med; 2010 Jan; 14(1-2):79-92. PubMed ID: 20041971
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of (18)F-labeled bile acid compound: a potential PET imaging agent for FXR-related diseases.
Jia L; Jiang D; Hu P; Li X; Shi H; Cheng D; Zhang L
Nucl Med Biol; 2014 Jul; 41(6):495-500. PubMed ID: 24776092
[TBL] [Abstract][Full Text] [Related]
18. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice.
Zhang L; Wang YD; Chen WD; Wang X; Lou G; Liu N; Lin M; Forman BM; Huang W
Hepatology; 2012 Dec; 56(6):2336-43. PubMed ID: 22711662
[TBL] [Abstract][Full Text] [Related]
19. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
Modica S; Moschetta A
FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
[TBL] [Abstract][Full Text] [Related]
20. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]